Friday, December 08, 2017 6:55:05 PM
Unless Howe comes out with a ridiculously convincing argument after the settlement for why JNSH remains completely tight-lipped about its future plans, I'll likely be moving on.
No, uplisting to NASDAQ isn't realistic as of right now.
I can't invest in an OTC company for years on end if they can't at least forecast realistic goals. The settlement/jury decision is the only thing that must happen; literally everything else is purely speculative because there's been no mention of it from JNSH.
I'd like to believe the story; they've definitely done a great job stabilizing the company, streamlining operations, and showing modest growth. That's the hallmark of a steady CEO, but not necessarily one that can take the next step.
Which is fine. I applaud JNSH for it. But that alone doesn't warrant long-term investment; Howe doesn't need public investment to grow organically in the manner that he has, and so there's no incentive to convince shareholders of future ROI.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM